BVF Inc. IL Sells 85,313 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

BVF Inc. IL trimmed its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 5.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,488,975 shares of the company’s stock after selling 85,313 shares during the period. Immunocore comprises approximately 1.7% of BVF Inc. IL’s holdings, making the stock its 21st largest holding. BVF Inc. IL’s holdings in Immunocore were worth $50,294,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Leonteq Securities AG bought a new position in Immunocore in the 4th quarter valued at $30,000. Harbour Investments Inc. boosted its position in Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the last quarter. Arax Advisory Partners boosted its position in Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after purchasing an additional 572 shares during the period. Finally, Osaic Holdings Inc. lifted its stake in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after purchasing an additional 1,700 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Stock Performance

IMCR stock opened at $28.55 on Thursday. The business’s 50-day moving average price is $29.45 and its two-hundred day moving average price is $32.04. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00. The firm has a market cap of $1.45 billion, a PE ratio of -51.91 and a beta of 0.74. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $27.56 and a 1-year high of $40.71.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.51. The firm had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share. As a group, research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Mizuho set a $38.00 price target on Immunocore in a research note on Thursday, February 19th. Needham & Company LLC increased their price target on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Jefferies Financial Group downgraded Immunocore from a “buy” rating to a “hold” rating and cut their price target for the company from $48.00 to $33.00 in a research note on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $56.71.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.